JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

11.42 -2.64

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.23

Max

11.7

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M -20M
Pardavimai	5.9M 40M
Pelno marža	-49.569
Darbuotojai	184
EBITDA	16M -19M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+95.35% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	455M 1.2B
Ankstesnė atidarymo kaina	14.06
Ankstesnė uždarymo kaina	11.42

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-10 23:26; UTC

Pagrindinės rinkos jėgos

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

2026-02-10 22:31; UTC

Uždarbis

Correction to America Movil 4Q Profit Article

2026-02-10 22:22; UTC

Uždarbis

America Movil 4Q Profit Jumps on Lower Financial Costs

2026-02-10 23:51; UTC

Rinkos pokalbiai

Uždarbis

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

2026-02-10 23:42; UTC

Rinkos pokalbiai

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

2026-02-10 23:40; UTC

Rinkos pokalbiai

Uždarbis

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

2026-02-10 23:21; UTC

Rinkos pokalbiai

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

2026-02-10 23:21; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-10 22:17; UTC

Rinkos pokalbiai

Australia's One Nation Now Commands Working Class Vote -- Market Talk

2026-02-10 22:15; UTC

Uždarbis

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

2026-02-10 22:10; UTC

Uždarbis

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

2026-02-10 22:10; UTC

Uždarbis

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

2026-02-10 22:09; UTC

Uždarbis

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

2026-02-10 22:09; UTC

Uždarbis

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

2026-02-10 22:01; UTC

Uždarbis

Intact Financial 4Q EPS C$5.24 >IFC.T

2026-02-10 21:54; UTC

Uždarbis

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

2026-02-10 21:53; UTC

Uždarbis

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

2026-02-10 21:51; UTC

Uždarbis

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

2026-02-10 21:51; UTC

Uždarbis

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

2026-02-10 21:51; UTC

Uždarbis

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

2026-02-10 21:51; UTC

Uždarbis

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

2026-02-10 21:51; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

2026-02-10 21:50; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

2026-02-10 21:50; UTC

Uždarbis

James Hardie Industries 3Q EPS 12c >JHX

2026-02-10 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-10 21:50; UTC

Uždarbis

James Hardie Industries 3Q Adj EPS 24c >JHX

2026-02-10 21:49; UTC

Uždarbis

James Hardie Industries 3Q Sales $1.24B >JHX

2026-02-10 21:49; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

2026-02-10 21:48; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

2026-02-10 21:47; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

95.35% į viršų

12 mėnesių prognozė

Vidutinis 22.29 USD 95.35%

Aukščiausias 29 USD

Žemiausias 16 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.